Despite the intervention during Phase 2 CRP, a non-neglectable proportion of patients (n = 33, 20.1%) showed a positive screening for depression (n = 4, 2.4%), anxiety (n = 15, 10.3%), or both (n = 14, 8.5%) at the end of the program (Table 1). This evidence concerns the gene CRP and depressive symptom measurement.